Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3.7% – What’s Next?

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) were down 3.7% on Monday . The company traded as low as $12.85 and last traded at $12.90. Approximately 78,881 shares traded hands during trading, a decline of 94% from the average daily volume of 1,328,051 shares. The stock had previously closed at $13.40.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on EYPT shares. HC Wainwright lifted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Citigroup raised their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, March 9th. TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Chardan Capital increased their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $32.20.

Eyepoint Pharmaceuticals Stock Performance

The stock has a 50-day moving average of $14.42 and a two-hundred day moving average of $14.52. The company has a market cap of $1.09 billion, a P/E ratio of -4.11 and a beta of 1.89.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). The company had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million. Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%. Research analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in EYPT. Jefferies Financial Group Inc. bought a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth $1,994,000. Corient Private Wealth LLC purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at $1,200,000. Walleye Capital LLC increased its holdings in Eyepoint Pharmaceuticals by 500.6% in the 2nd quarter. Walleye Capital LLC now owns 199,449 shares of the company’s stock worth $1,877,000 after buying an additional 166,243 shares in the last quarter. Aberdeen Group plc raised its position in Eyepoint Pharmaceuticals by 101.6% in the 4th quarter. Aberdeen Group plc now owns 1,605,984 shares of the company’s stock worth $29,341,000 after buying an additional 809,182 shares during the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in Eyepoint Pharmaceuticals in the 3rd quarter worth about $9,256,000. Institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.